Inovio Pharmaceuticals, Inc. - Common Stock (INO)

INO earnings call for the period ending December 31, 2024.

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.

Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses.

Inovio Pharmaceuticals shares are trading lower by 38% during Friday's session. The company priced a public offering of 10 million shares of common stock and accompanying warrants.

U.S. stock futures advanced on Friday in premarket after declining on Thursday. The futures of all four major indices were trading higher.

INO earnings call for the period ending September 30, 2024.

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

INO earnings call for the period ending June 30, 2024.

INO stock results show that Inovio Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Both biotechs have been struggling for a while, but there might be some hope for them.

Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP treatment.

INO earnings call for the period ending March 31, 2024.